TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16156112

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 25 microg, 2 doses hourly for 23.33 hours
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 40 microg, 2 doses hourly over 23.33 hours
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 40 microg, 6, 18, 36 and 80 doses over 1, 3, 6 and 13.33 hours
Number of subjects: 89
Study: 11982795

Group type: EXPERIMENTAL
Intervention: Midazolam (0.4 mg/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sodium thiopental (5 mg/kg)
Number of subjects: 65
Study: 9516618

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and concurrent radiation for 6 weeks with no adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and carboplatin with hyperfractionated radiation, followed by two cycles of adjuvant paclitaxel and carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent weekly paclitaxel plus radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and radiation therapy
Number of subjects: 0
Study: 8719668

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol with midazolam
Number of subjects: 40
Study: 2561190

Group type: EXPERIMENTAL
Intervention: Oral itraconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 69126

Group type: EXPERIMENTAL
Intervention: Gentamicin combined with lincomycin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gentamicin combined with metronidazole
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 52
Study: 31400517

Group type: EXPERIMENTAL
Intervention: Clinical exome sequencing (CES)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 186
Study: 28389911

Group type: EXPERIMENTAL
Intervention: Nursing education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 26224199

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 3825

Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 3825

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 3825

Group type: EXPERIMENTAL
Intervention: Region
Number of subjects: 3825
Study: 23024219

Group type: EXPERIMENTAL
Intervention: High phosphate (HP, 2000 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low phosphate (750 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low phosphate plus phosphate binder (aluminum hydroxide, 500 mg thrice daily with meals)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 30
Study: 21610514

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 19387475

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous ghrelin treatment
Number of subjects: 12
Study: 16988792

Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg per day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15497371

Group type: EXPERIMENTAL
Intervention: Clockwise rotation (CW)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Counterclockwise rotation (CCW)
Number of subjects: 28
Study: 11479485

Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A (0.75, 1.5, 3, 6, or 8 mg/d subcutaneously)
Number of subjects: 933

Group type: COMPARATOR
Intervention: Enoxaparin (30 mg subcutaneously every 12 hours)
Number of subjects: 933
Study: 9308789

Group type: EXPERIMENTAL
Intervention: 200 mg testosterone oenanthate (TE) weekly i.m. injections
Number of subjects: 33
Study: 7871362

Group type: EXPERIMENTAL
Intervention: Maximal biting force with splint covering tooth 11
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximal biting force with splint covering teeth 13-23
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bite force during successive trials with single tooth
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bite force during successive trials with multiple teeth
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tactile sensibility of tooth 11 and its antagonists
Number of subjects: 10
Study: 3063134

Group type: EXPERIMENTAL
Intervention: Ranitidine (6 x 50 to 6 x 100 mg daily i.v.)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sucralfate (6 x 1 g via gastric tube or per os)
Number of subjects: 84
Study: 29766842

Group type: EXPERIMENTAL
Intervention: Once-daily oral antibiotic prophylaxis using either 50 mg of nitrofurantoin, 100 mg of trimethoprim, or 250 mg of cefalexin for 12 months
Number of subjects: 404

Group type: COMPARATOR
Intervention: No prophylaxis for 12 months
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Once-daily oral antibiotic prophylaxis
Number of subjects: 404
Study: 28404658

Group type: EXPERIMENTAL
Intervention: Longitudinal mean M-value (over time)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Within-day glycemic variability measures
Number of subjects: 0
Study: 27553950

Group type: EXPERIMENTAL
Intervention: Parent training intervention (The Incredible Years), 6 sessions
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (services as usual)
Number of subjects: 117
Study: 23390041

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (60 mg/day eicosapentaenoic acid and 252 mg/day docosahexaenoic acid) for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study: 21330557

Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 168

Group type: COMPARATOR
Intervention: Transarterial lipiodol chemoembolization (TACE)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: TACE followed by hepatic resection
Number of subjects: 168

Group type: COMPARATOR
Intervention: TACE with good response but refused hepatic resection
Number of subjects: 168

Group type: COMPARATOR
Intervention: Initial hepatic resection
Number of subjects: 168
Study: 19001450

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (LAMB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study: 17075851

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day, 15 mg/day, 35 mg/week in Europe, 50 mg/week in North America)
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 2483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2483
Study: 15521562

Group type: EXPERIMENTAL
Intervention: Iodised salt consumption
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Urinary iodine level measurement
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Salt iodine level measurement
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Drinking water iodine level measurement
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Thiocyanate level measurement
Number of subjects: 969
Study: 11350437

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy using a 33‐mm circular stapling device (group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional open haemorrhoidectomy (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy (group 2)
Number of subjects: 100
Study: 10771879

Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU) with measles vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo with measles vaccine
Number of subjects: 100
Study: 7714154

Group type: EXPERIMENTAL
Intervention: Microsurgical lysis of filmy adhesions
Number of subjects: 51

Group type: COMPARATOR
Intervention: In-vitro fertilization (IVF)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lysis of filmy adhesions by laparotomy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lysis of filmy adhesions by laparoscopy
Number of subjects: 51
Study: 3296724

Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 24
Study: 28669666

Group type: EXPERIMENTAL
Intervention: Nutriose®06 (resistant dextrin) 10 g/d for 8 weeks
Number of subjects: 55
Study: 27749900

Group type: EXPERIMENTAL
Intervention: Lambda/RBV/TVR
Number of subjects: 838

Group type: COMPARATOR
Intervention: Alfa/RBV/TVR
Number of subjects: 838
Study: 24965504

Group type: EXPERIMENTAL
Intervention: Dexpramipexole (75 mg and 150 mg single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Number of subjects: 0
Study: 22341290

Group type: EXPERIMENTAL
Intervention: Burch urethropexy
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 655
Study: 19919904

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: Baseline median seizure frequency
Number of subjects: 5662

Group type: COMPARATOR
Intervention: Placebo drift
Number of subjects: 5662
Study: 18245121

Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization prior to vascular surgery
Number of subjects: 377

Group type: COMPARATOR
Intervention: No revascularization (Control)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Diabetes (as a predictor)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Age >70 (as a predictor)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Abdominal aortic surgery (as a predictor)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Angina (as a predictor)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Baseline STT abnormalities (as a predictor)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: MI status at 2.5 years post-surgery
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: MI in diabetic patients (as a predictor of long-term mortality)
Number of subjects: 377
Study: 16175132

Group type: EXPERIMENTAL
Intervention: Pliva Cyclosporine Soft Gelatin Capsules (USP Modified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoral (cyclosporine soft gelatin capsules, USP Modified)
Number of subjects: 0
Study: 12789824

Group type: EXPERIMENTAL
Intervention: Betaserc (16 mg, 3 times daily before meal)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cinnarizine (25 mg, 3 times daily)
Number of subjects: 56
Study: 10830739

Group type: EXPERIMENTAL
Intervention: Randomized treatment group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-randomized treatment group
Number of subjects: 68
Study: 8676806

Group type: EXPERIMENTAL
Intervention: Diet and blood pressure interventions
Number of subjects: 840
Study: 8275622

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 300
Study: 3829014

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy with doxorubicin and vincristine, surgery, or radiotherapy followed by additional chemotherapy with the same drug regimen
Number of subjects: 52
Study: 30336847

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control
Number of subjects: 244
Study: 27458667

Group type: EXPERIMENTAL
Intervention: Electrical stimulation ventilatory feedback (ESVF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (ESVF device attached but not activated)
Number of subjects: 23
Study: 24726579

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (olanzapine, perphenazine, quetiapine, risperidone, ziprasidone)
Number of subjects: 753
Study: 22540248

Group type: EXPERIMENTAL
Intervention: Indwelling catheterization
Number of subjects: 139

Group type: COMPARATOR
Intervention: Intermittent catheterization
Number of subjects: 139
Study: 20634666

Group type: EXPERIMENTAL
Intervention: Full construct vaccine (recombinant fowlpox virus carrying genes for HIV Gag-Pol and IFN-gamma)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Partial construct (without IFN-gamma)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with IgG2 anti-p24 and 'high-affinity' polymorphism of FcgammaRIIa
Number of subjects: 23
Study: 18811597

Group type: EXPERIMENTAL
Intervention: WMTA Angelus
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MTA Bio
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pro‐Root MTA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Portland cement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (10 teeth)
Number of subjects: 70
Study: 16164709

Group type: EXPERIMENTAL
Intervention: C. indicum extract-based cream (n = 125)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (n = 121)
Number of subjects: 246
Study: 12911418

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg/day
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 10731407

Group type: EXPERIMENTAL
Intervention: Uncompressed images
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Compressed images at CR 6:1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Compressed images at CR 10:1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Compressed images at CR 16:1
Number of subjects: 21
Study: 8666350

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1531215

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy plus etanidazole (2 g/m2 i.v. 30 to 60 min before radiotherapy each Monday, Wednesday, and Friday to 34 g/m2 in 17 doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 33
Study: 2580144

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg twice daily)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control state (no ketanserin)
Number of subjects: 2
Study: 30321655

Group type: EXPERIMENTAL
Intervention: Twice-daily GSP301 (665 μg olopatadine and 25 μg mometasone)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Once-daily GSP301 (665 μg olopatadine and 50 μg mometasone)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (twice-daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AzeFlu (137 μg azelastine and 50 μg fluticasone, twice-daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Olopatadine (twice-daily)
Number of subjects: 180
Study: 29957728

Group type: EXPERIMENTAL
Intervention: Polyphenol blend (PPB) supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 38
Study: 27169789

Group type: EXPERIMENTAL
Intervention: BPT + DIS
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BPT + DIS + AM
Number of subjects: 110

Group type: COMPARATOR
Intervention: BPT + S
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: AM
Number of subjects: 110
Study: 25041265

Group type: EXPERIMENTAL
Intervention: Intra-operative perihepatic drain (IPD)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No drains (control group)
Number of subjects: 199
Study: 23200625

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg or 100/12.5 μg once daily for 7 days in patients with hepatic impairment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg or 100/12.5 μg once daily for 7 days in patients with moderate hepatic impairment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg or 100/12.5 μg once daily for 7 days in patients with renal and hepatic impairment
Number of subjects: 44
Study: 20039787

Group type: EXPERIMENTAL
Intervention: Acupuncture (n=134)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Self-care (n=133)
Number of subjects: 267

Group type: COMPARATOR
Intervention: General population (NOWAC study)
Number of subjects: 267
Study: 18806065

Group type: EXPERIMENTAL
Intervention: Automated bolus doses of 5 mL every hour of 0.125% levobupivacaine for 24 h
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous infusion of 0.125% levobupivacaine with an infusion rate of 5 mL/h for 24 h
Number of subjects: 44
Study: 16106493

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (D2)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Superextended lymphadenectomy (D3)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Prolonged operating time
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Body mass index ≥ 25 kg/m2
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 523
Study: 12394892

Group type: EXPERIMENTAL
Intervention: Medical care with physical therapy
Number of subjects: 681

Group type: COMPARATOR
Intervention: Chiropractic care
Number of subjects: 681

Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 681

Group type: COMPARATOR
Intervention: Medical care without physical therapy
Number of subjects: 681
Study: 10413128

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 50
Study: 7769290

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 2255266

Group type: EXPERIMENTAL
Intervention: Norethisterone (NET)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Natural micronized progesterone (NMP)
Number of subjects: 80
Study: 376131

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg 3 times daily)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Tamoxifen (10 mg 3 times daily) plus Medroxyprogesterone acetate (100 mg once daily)
Number of subjects: 101
Study: 31985125

Group type: EXPERIMENTAL
Intervention: Real-time geriatric assessment report provided to clinicians
Number of subjects: 135

Group type: COMPARATOR
Intervention: No geriatric assessment report provided to clinicians (Control)
Number of subjects: 135
Study: 31679821

Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA 1 g/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA 2 g/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA 4 g/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA after HF breakfast on day 15
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA (all doses)
Number of subjects: 42
Study: 28733301

Group type: EXPERIMENTAL
Intervention: 3D navigation template guided surgery
Number of subjects: 0
Study: 25611190

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage
Number of subjects: 193

Group type: COMPARATOR
Intervention: Non-lavage
Number of subjects: 193
Study: 23529917

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21367953

Group type: EXPERIMENTAL
Intervention: Refeeding intervention after a median of 95 days (IQR 88-125 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Refeeding intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study: 19232936

Group type: EXPERIMENTAL
Intervention: two mg of butorphanol in 10 mL of 0.125% bupivacaine (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: two mg of butorphanol in 10 mL of 0.25% bupivacaine (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: two mg of butorphanol in 10 mL of normal saline (Group 1)
Number of subjects: 60
Study: 17761370

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 23
Study: 15095233

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg q.d. for 6 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 200
Study: 11546717

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg with fentanyl 0.02 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg without fentanyl (Control group)
Number of subjects: 44
Study: 9511041

Group type: EXPERIMENTAL
Intervention: Doxycycline therapy for 4 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 34
Study: 8141214

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard obstetric care without amnioinfusion
Number of subjects: 105
Study: 3375787

Group type: EXPERIMENTAL
Intervention: Oral, attenuated live Salmonella typhi Ty 21a vaccine (Vivotif)
Number of subjects: 44000

Group type: EXPERIMENTAL
Intervention: Lyophilized vaccine reconstituted in a buffer solution
Number of subjects: 44000

Group type: COMPARATOR
Intervention: Initially marketed formulation (2 bicarbonate capsules + vaccine capsule)
Number of subjects: 44000
Study: 1115014

Group type: EXPERIMENTAL
Intervention: 1.4 g/kg body weight protein intake
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2.8 g/kg body weight protein intake
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group receiving adequate protein intake
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-protein diets
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 100 g of protein/day
Number of subjects: 2
Study: 31722153

Group type: EXPERIMENTAL
Intervention: Secondary surgical cytoreduction followed by platinum-based chemotherapy
Number of subjects: 485

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 485
Study: 28544495

Group type: EXPERIMENTAL
Intervention: Interspinous fastener (ISF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pedicle screws
Number of subjects: 46
Study: 26775456

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 80
Study: 23233321

Group type: EXPERIMENTAL
Intervention: ALX‐0081
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 21245879

Group type: EXPERIMENTAL
Intervention: Sucralose (0.083% w/v)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modified sham-feeding of sucralose (0.083% w/v)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maltodextrin (50% w/v maltodextrin + 0.083% sucralose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study: 18285619

Group type: EXPERIMENTAL
Intervention: 70 mg lisdexamfetamine capsule
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine in solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: 70 mg lisdexamfetamine capsule with high-fat meal
Number of subjects: 18